alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with paroxetine in 1 studies
Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (paroxetine) | Trials (paroxetine) | Recent Studies (post-2010) (paroxetine) |
---|---|---|---|---|---|
90 | 1 | 2 | 4,257 | 1,031 | 1,031 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bergeron, R; De Montigny, C; Debonnel, G | 1 |
1 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and paroxetine
Article | Year |
---|---|
Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands.
Topics: 1-Naphthylamine; Animals; Antidepressive Agents; Clorgyline; Electrophysiology; Haloperidol; Male; N-Methylaspartate; Paroxetine; Pyramidal Cells; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Sertraline; Tranylcypromine | 1993 |